CGEM ▼ -5.3% - Cullinan Therapeutics, Inc. $CGEM - New Drug Application Submission Initiated for Zipalertinib Plus Chemotherapy in First-Line EGFR Exon 20 Insertion Mutation NSCLC for Review Under FDA Real-Time Oncology Review Program 01-OCT-2026 07:30 PM ET